Drug Trial Radar · NCT01444430
A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents
Last checked: Nov 19, 2026Latest source record: Dec 15, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
12,460
Actual
Start
Dec 2011
Primary completion
Oct 2015
Study completion Oct 2015
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Sep 30, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 12 years, up to 130 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate the safety of Symbicort compared to inhaled corticosteroid alone during 6 months in adult and adolescent patients with asthma
Conditions
- Asthma
Interventions
Symbicort pMDIDrug
Patients were randomized to Symbicort and assigned to one of the following treatments (based upon ACQ at baseline and prior asthma therapy): Symbicort pMDI 80/4.5 μg x 2 actuations bid (morning and evening) or Symbicort pMDI 160/4.5 μg x 2 actuations bid (morning and evening), for oral inhalation.
budesonide pMDIDrug
Patients were randomized to budesonide and assigned to one of the following treatments (based upon ACQ at baseline and prior asthma therapy): budesonide pMDI 80 μg x 2 actuations bid (morning and evening) or budesonide pMDI 160 μg x 2 actuations bid (morning and evening), for oral inhalation.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Experiencing an Event in the Composite Endpoint (Asthma-related Death, Asthma-related Intubation or Asthma-related Hospitalization)Time frame: Up to 27 weeks
- Number of Participants Experiencing an Event Included in the Definition of Asthma ExacerbationTime frame: Up to 26 weeks
Locations
340 sites in 26 countries. Site status is shown where the registry gives one.
Research Site
Birmingham, Alabama
Research Site
Huntsville, Alabama
Research Site
Anchorage, Alaska
Research Site
Gilbert, Arizona
Research Site
Glendale, Arizona
Research Site
Mesa, Arizona
Research Site
Tucson, Arizona
Research Site
Fort Smith, Arkansas
Research Site
Little Rock, Arkansas
Research Site
Alhambra, California
Research Site
Anaheim, California
Research Site
Arvin, California
Research Site
Bellflower, California
Research Site
Buena Park, California
Research Site
Costa Mesa, California
Research Site
Encinitas, California
Research Site
Escondido, California
Research Site
Fountain Valley, California
Research Site
Glendale, California
Research Site
Long Beach, California
Research Site
Los Angeles, California
Research Site
Newport Beach, California
Research Site
Northridge, California
Research Site
Palmdale, California
Research Site
Pasadena, California
Research Site
Poway, California
Research Site
Riverside, California
Research Site
Roseville, California
Research Site
San Diego, California
Research Site
San Jose, California
Research Site
Santa Ana, California
Research Site
Stockton, California
Research Site
Tustin, California
Research Site
Walnut Creek, California
Research Site
Denver, Colorado
Research Site
Thornton, Colorado
Research Site
Norwalk, Connecticut
Research Site
Waterbury, Connecticut
Research Site
Altamonte Springs, Florida
Research Site
Clearwater, Florida
Showing 40 of 340 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.